报价延迟最少15分钟:2025/11/17 17:21 EST
盘后时段
|
||||
|
4.25 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.26
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.62/-1.83
|
|
企业价值
159.05M
|
| 资产负债 |
|
每股账面净值
3.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.97M
|
|
每股收益
0.25
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/17 17:21 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment. |
